Lopressor Hct

Atrial Fibrillation, Thyroid Crisis, Migraine + 9 more
Treatment
4 FDA approvals
20 Active Studies for Lopressor Hct

What is Lopressor Hct

MetoprololThe Generic name of this drug
Treatment SummaryMetoprolol is a type of medication used to reduce blood pressure. It comes in two forms, immediate-release and extended-release. The extended-release version is more widely used because it has lower levels of absorption into the bloodstream. Metoprolol has been widely prescribed in the US, Netherlands, and New Zealand since it was approved by the FDA in 1978. It is one of the most commonly used beta-blockers for treating high blood pressure.
Lopressoris the brand name
image of different drug pills on a surface
Lopressor Hct Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Lopressor
Metoprolol
1978
983

Approved as Treatment by the FDA

Metoprolol, also known as Lopressor, is approved by the FDA for 4 uses including Hypertensive disease and Hypertension .
Hypertensive disease
Used to treat High Blood Pressure (Hypertension) in combination with Hydrochlorothiazide
Hypertension
Used to treat nonresponsive to antihypertensive monotherapy in combination with Hydrochlorothiazide
Hemodynamically Stable
Heart Attack

Effectiveness

How Lopressor Hct Affects PatientsMetoprolol is used to slow the heart rate, reduce cardiac excitability, and decrease the demand for oxygen in the heart. Studies have shown that taking metoprolol can reduce the risk of sudden cardiac death and heart attack. In clinical trials done in 1990, it was found that long-term use of metoprolol after a heart attack could reduce mortality and re-infarction rates by 17%.
How Lopressor Hct works in the bodyMetoprolol reduces the activity of certain receptors in the heart, slowing the heart rate and reducing the amount of blood flowing through the heart. This drug has no effect on other parts of the body, such as the nervous system.

When to interrupt dosage

The suggested portion of Lopressor Hct is contingent upon the identified condition, including Hemodynamically Stable, Thyroid Crisis and Atrial Fibrillation. The amount of dosage is specified, as per the method of delivery (e.g. Tablet, coated or Tablet - Oral) recorded in the table beneath.
Condition
Dosage
Administration
Chest Pain
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Heart Attack
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Hypertensive disease
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Hypertension
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Migraine Disorders
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Atrial Fibrillation
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Thyroid Crisis
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Migraine
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Hypesthesia
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Hypesthesia
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Hemodynamically Stable
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated
Tachycardia, Supraventricular
, 50.0 mg, 100.0 mg, 5.0 mg/mL, 25.0 mg, 200.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL, 23.75 mg, 190.0 mg, 90.0 mg, 47.5 mg, 37.5 mg, 75.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intravenous, Kit, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated - Oral, Tablet, coated

Warnings

Lopressor Hct Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Metoprolol may interact with Pulse Frequency
Heart Block
Do Not Combine
Shock, Cardiogenic
Do Not Combine
Heart Decompensation
Do Not Combine
Pulse Frequency
Do Not Combine
severe bradycardia
Do Not Combine
Sick Sinus Syndrome
Do Not Combine
There are 20 known major drug interactions with Lopressor Hct.
Common Lopressor Hct Drug Interactions
Drug Name
Risk Level
Description
4-Bromo-2,5-dimethoxyphenethylamine
Major
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Metoprolol.
Abediterol
Major
The therapeutic efficacy of Abediterol can be decreased when used in combination with Metoprolol.
Adrafinil
Major
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Metoprolol.
Agrostis gigantea pollen
Major
The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Metoprolol.
Agrostis stolonifera pollen
Major
The risk of a hypersensitivity reaction to Agrostis stolonifera pollen is increased when it is combined with Metoprolol.
Lopressor Hct Toxicity & Overdose RiskThe highest toxic dose of metoprolol in rats is estimated to be between 3090 and 4670 milligrams per kilogram. Overdosing on metoprolol may cause a slow heartbeat, low blood pressure, difficulty breathing, and heart failure. In the event of an overdose, treatment involves emptying the stomach and then addressing the symptoms. There is no evidence to suggest that metoprolol causes cancer, genetic mutations, or infertility. If taken for a long period of time at high doses, it has been linked to small harmless lung tumors.
image of a doctor in a lab doing drug, clinical research

Lopressor Hct Novel Uses: Which Conditions Have a Clinical Trial Featuring Lopressor Hct?

319 active clinical trials are currently investigating the potential of Lopressor Hct to mitigate Hypesthesia, Thyroid Crisis and Hypertensive diseases.
Condition
Clinical Trials
Trial Phases
Atrial Fibrillation
94 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1
Chest Pain
2 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Heart Attack
23 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3
Thyroid Crisis
0 Actively Recruiting
Hypesthesia
8 Actively Recruiting
Not Applicable, Phase 1
Hemodynamically Stable
0 Actively Recruiting
Tachycardia, Supraventricular
0 Actively Recruiting
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Hypesthesia
2 Actively Recruiting
Not Applicable
Hypertension
0 Actively Recruiting
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Migraine Disorders
1 Actively Recruiting
Phase 3

Lopressor Hct Reviews: What are patients saying about Lopressor Hct?

5Patient Review
11/16/2013
Lopressor Hct for High Blood Pressure
After Lupron treatment, I started having "heat flashes" or "sweat fits". However, this stopped happening about three years ago. Some have suggested that metoprolol tartrate may be the source of the problem.
5Patient Review
12/21/2013
Lopressor Hct for High Blood Pressure
I've been taking this medication for 15 years with no issues whatsoever.
5Patient Review
3/18/2009
Lopressor Hct for High Blood Pressure
4Patient Review
4/3/2010
Lopressor Hct for High Blood Pressure
I was really pleased with this medication. I'm sensitive to a lot of drugs, but this one didn't bother my stomach or leave me feeling irritated.
4Patient Review
6/17/2009
Lopressor Hct for High Blood Pressure

Patient Q&A Section about lopressor hct

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does metoprolol have hydrochlorothiazide in it?

"For the extended-release tablets, the recommended starting dose for adults is one tablet containing 25 mg of metoprolol and 12.5 mg of hydrochlorothiazide once daily. Your doctor may adjust the dose as needed."

Answered by AI

Is Lopressor a water pill?

"Lopressor HCT is a combination of a beta-blocker and thiazide diuretic used to treat high blood pressure. Lopressor HCT is available in generic form."

Answered by AI

What is Lopressor HCT used for?

"Metoprolol is a beta-blocker that works by blocking the action of certain natural chemicals in your body (such as epinephrine) that affect the heart and blood vessels. This results in a decrease in heart rate and blood pressure. Hydrochlorothiazide is a "water pill" (diuretic) that causes you to make more urine, which helps your body get rid of extra salt and water.

This medication is for treating high blood pressure. It contains two medications, metoprolol and hydrochlorothiazide. Metoprolol is a beta-blocker that works by blocking the action of certain natural chemicals that affect the heart and blood vessels, which results in a decrease in heart rate and blood pressure. Hydrochlorothiazide is a "water pill" (diuretic) that causes you to make more urine, which helps your body get rid of extra salt and water."

Answered by AI

Is metoprolol tartrate the same as hydrochlorothiazide?

"Hydrochlorothiazide is a thiazide diuretic that helps to remove excess water from the body. Metoprolol is a beta-blocker that works to block the effects of adrenaline, helping to lower blood pressure. Together, these two medications are used to treat hypertension, or high blood pressure."

Answered by AI

Clinical Trials for Lopressor Hct

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Have you considered Lopressor Hct clinical trials? We made a collection of clinical trials featuring Lopressor Hct, we think they might fit your search criteria.Go to Trials
Image of Mission Cardiovascular Research Institute in Fremont, United States.

REGN7508 + REGN9933 for Atrial Fibrillation

18+
All Sexes
Fremont, CA
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Phase 2
Recruiting
Mission Cardiovascular Research Institute (+4 Sites)Clinical Trial ManagementRegeneron Pharmaceuticals
Have you considered Lopressor Hct clinical trials? We made a collection of clinical trials featuring Lopressor Hct, we think they might fit your search criteria.Go to Trials
Image of University of the Fraser Valley in Chilliwack, Canada.

Mind-Body App + Movement Program for Chronic Pain

19 - 75
All Sexes
Chilliwack, Canada
The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic/persistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).
Waitlist Available
Has No Placebo
University of the Fraser ValleyCynthia J Thomson, PhD
Image of Baystate Medical Center in Springfield, United States.

Consent Approaches for Heart Disease Rehabilitation

18+
All Sexes
Springfield, MA
Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend. New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation. In preparation for a larger trial, patients will also be randomly assigned to four different ways of seeking their permission to be in a research study. The investigators will see if these approaches affect how many people participate in the research project. The two main goals of this study is to understand: 1. If the consent approach type impacts participation rates in the research study 2. If the multi-component intervention (case management, financial incentives, text messages, and physical activity coaching) improves cardiac rehabilitation participation within 3 months.
Recruiting
Has No Placebo
Baystate Medical CenterQuinn R Pack, MD, MSc
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamPankaj Arora, MD, FAHA
Have you considered Lopressor Hct clinical trials? We made a collection of clinical trials featuring Lopressor Hct, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security